Neurology® Podcast

Latest Episodes:

Delayed Recall - Concussion and Chronic Traumatic Encephalopathy (September 2017) Sep 01, 2017

Show notes

The first interview in this month's Delayed Recall episode is from March 17, 2015; in this interview, Dr. Howard Goodkin and Dr. Robert Stern discuss the effect that age of first exposure to football has on later-life cognitive impairment in former NFL players. The second interview, from August 29, 2017, is a discussion between Dr. Jason Crowell and Dr. Jesse Mez about a July 2017 JAMA paper on occurrence of CTE in American football players. In the third interview, Dr. Christopher Giza speaks with Dr. John Hart about Dr. Hart's paper regarding depressive symptoms and white matter dysfunction in retired NFL players with concussion history. This interview originally appeared in the July 1, 2013 episode. The fourth and final interview is a discussion between Dr. Ted Burns and former NFL player Ben Utecht, regarding Mr. Utecht's Sept 23, 2014 editorial, "Concussed."

August 29 2017 Issue Aug 28, 2017

Show notes

Show description/summary:1) Prognostic relevance of MOG antibodies in children with an acquired demyelinating syndrome2) What's Trending: CTE and American football playersThis podcast begins and closes with Dr. Robert Gross, Editor-in-Chief, briefly discussing highlighted articles from the August 29, 2017 issue of Neurology. In the first segment, Dr. Nicholas Brenton talks with Dr. Kevin Rostásy about his paper on the prognostic relevance of MOG antibodies in children with an acquired demyelinating syndrome. In the second part of the podcast, Dr. Jason Crowell focuses his interview with Dr. Jesse Mez on chronic traumatic encephalopathy and American football players. Disclosures can be found at Neurology.org.DISCLOSURES: Dr. Rostásy serves on a scientific advisory board for Novartis regarding a fingolimod project, and has received speaker honoraria for Merck-Serono.Dr. Smith serves on the Celegene data monitoring committee; serves as editor for NeuroLearn; has consulted for Regenesis, Allergan, and Viromed; and receives research support from Impeto Medical, and NIDDK (DK064814), NINDS (U10NS077305 and U10NS086606).All other participants report no disclosures.

August 22 2017 Issue Aug 21, 2017

Show notes

Show description/summary:1) Oral fluoroquinolones and risk of secondary pseudotumor cerebri syndrome2) Neurology Today: FDA Approves Edaravone for ALS: Phase 3 Trial Finds It Slows ProgressionThis podcast begins and closes with Dr. Robert Gross, Editor-in-Chief, briefly discussing highlighted articles from the August 22, 2017 issue of Neurology. In the first segment, Dr. Halley Alexander talks with Mr. Mohit Sodhi about his paper on oral fluoroquinolones and risk of secondary pseudotumor cerebri syndrome. In the second part of the podcast, Dr. Kelly Gwathmey focuses her interview with Dr. Terry Heiman-Patterson on a Neurology Today® story about the FDA-approval of edaravone for the treatment of ALS. Disclosures can be found at Neurology.org.DISCLOSURES: All participants report no disclosures.

August 15 2017 Issue Aug 14, 2017

Show notes

Show description/summary:1) Quality improvement in neurology: Inpatient and emergency care quality measure set executive summary 2) Neurology Today: Incidental findings and normal variants on MRI of the brain in adults for primary headachesIn the first segment, Dr. Jason Crowell talks with Dr. Paul Vespa about his paper on quality improvement in inpatient and emergency neurologic care. In the second part of the podcast, Dr. Teshamae Monteith focuses her interview with Dr. Randolph Evans on a Neurology Today® story about incidental findings and normal variants on brain MRI for primary headache in adults. Disclosures can be found at Neurology.org.DISCLOSURES: Dr. Vespa serves on scientific advisory boards for Intouch Health, Edge Pharmaceuticals, and Sage Pharmaceuticals; serves on editorial boards for Critical Care Medicine, Neurocritical Care, and Surgical Neurology International; has consulted for General Electric and Neuren; receives research support from NINDS; holds stock in Intouch Health and stock options in Pfizer; and gave expert testimony about brain trauma.Dr. Monteith serves as an editorial advisory board member for Neurology Now and receives research support from the NIH.Dr. Crowell and Dr. Evans report no disclosures.

August 8 2017 Issue Aug 07, 2017

Show notes

Show description/summary:1) Neurology® Clinical Practice: Barriers and Facilitators to ER Physician Use of the Test and Treatment for BPPV2) What's Trending: New crowd-funding research initiative from ABFIn the first segment, Dr. Jim Siegler talks with Dr. Kevin Kerber and Dr. William Meurer about their Neurology® Clinical Practice article on ER physician use of the test and treatment for benign paroxysmal positional vertigo. In the second part of the podcast, Dr. Andy Southerland focuses his interview with Dr. Robert Griggs and Jane Ransom on the new crowd-funding research initiative from the American Brain Foundation. Disclosures can be found at Neurology.org.DISCLOSURES: Dr. Siegler serves on the Resident and Fellow Section Team for Neurology, and has received research support from NIH (U10 StrokeNet grant, 2017-2018).Jane Ransom is Executive Director of the American Brain Foundation.Dr. Kerber received funding for travel from Elsevier Inc. and the American Academy of Neurology; receives royalties from the publication of the book Clinical Neurophysiology of the Vestibular System, 4th edition; is a consultant for the American Academy of Neurology, University of California San Francisco (including work on a project funded by AstraZeneca), and Best Doctors, Inc.; receives research support from the NIH; received speaker honoraria from American Academy of Neurology and University of California San Francisco and loan repayment award from the NIH; reviewed legal records of Phil Pearsons, MD, JD and National Medical Consultants.Dr. Meurer serves as Decision Editor for the Annals of Emergency Medicine; serves as Methodology Statistics Reviewer for Academic Emergency Medicine; and has received research support from the Massey Foundation for TBI research. Dr. Griggs has served on scientific advisory boards for National Hospital Queen Square, Marathon Pharmaceuticals, Taro Pharmaceuticals, and Sarepta Pharmaceuticals; has served on the data monitoring and safety board for PTC Therapeutics, Inc.; serves on the editorial board for NeuroTherapeutics and Current Treatment Opinions in Neurology; serves as Correspondence Editor for Neurology; receives publishing royalties from Andreoli and Carpenter's Cecil Essentials of Medicine (Eighth Edition, Elsevier), Cecil Textbook of Medicine (multiple editions, Elsevier), and Evaluation and Treatment of Myopathies (2014, Oxford); has consulted for Marathon, PTC Therapeutics, Sarepta, Taro Pharmaceuticals, Idera Pharmaceuticals, and Strongbridge Pharmaceuticals; receives data royalties and research support from Taro Pharmaceuticals and Marathon Pharmaceuticals; has received research support from NINDS (T32 NS07338, 5U01NS061799, 1R13NS084687), the FDA (R01 FD003923), Parent Project Muscular Dystrophy, Inc., and the Muscular Dystrophy Association; and is the recent past Chair of Executive Committee of the Muscle Study Group.

August 1 2017 Issue Jul 31, 2017

Show notes

Show description/summary:1) On being sick: Musings about kindness, side effects, and slowing down2) Resident & Fellow Section Update: Annual Writing AwardIn the first segment, Dr. Alberto Espay talks with Dr. Ted Burns about his Special Editorial, "On being sick: Musings about kindness, side effects, and slowing down." In the second part of the podcast, Dr. Andy Southerland focuses his interview with Dr. John Millichap on the annual Resident & Fellow writing award. Disclosures can be found at Neurology.org.DISCLOSURES:Dr. Espay serves as Associate Editor for the Journal of Clinical Movement Disorders; serves as an editorial board member of Parkinsonism and Related Disorders and The European Neurological Journal; serves on the scientific advisory board for Solvay Pharmaceuticals, Inc. (now Abbvie), Chelsea Therapeutics International, Ltd., Teva Pharmaceutical Industries Ltd., Impax, Merz Pharmaceuticals, Inc., Pfizer Inc, Solstice Neurosciences, Eli Lilly and Company, ACADIA Pharmaceuticals, Inc. and USWorldMeds; is a consultant for Chelsea Therapeutics International, Ltd., Solvay Pharmaceuticals, Inc. (now Abbvie), ACADIA Pharmaceuticals, Inc., Cynapsus and Lundbeck, Inc; receives royalties for publications of books from Lippincott, Williams & Wilkins and Cambridge University Press; serves on the speakers' bureau of UCB, Teva Pharmaceutical Industries Ltd., American Academy of Neurology and Movement Disorders Society; receives research support from the CleveMed/Great Lake Neurotechnilogies, Michael J. Fox Foundation and the NIH.Dr. Burns serves as Podcast Editor for Neurology®; and has received research support for consulting activities with UCB, CSL Behring, Walgreens and Alexion Pharmaceuticals, Inc. All other participants report no disclosures.Dr. Southerland serves as Podcast Editor for Neurology; receives research support from the American Heart Association-American Stroke Association National Clinical Research Program, American Academy of Neurology, American Board of Psychiatry and Neurology, Health Resources Services Administration and the NIH; has a provisional patent application titled: "Method, system and computer readable medium for improving treatment times for rapid evaluation of acute stroke via mobile telemedicine;" and gave legal expert review.Dr. Millichap has received speaker honoraria from Invitae; serves on the editorial board for Neurology and Pediatric Neurology Briefs; receives publishing royalties from BMJ Best Practice and UpToDate; and has received research support from UCB Pharma, Thrasher Research Fund, and Citizens United for Research in Epilepsy.

July 25 2017 Issue Jul 24, 2017

Show notes

Show description/summary:1) Neurology and the Humanities: Discovering the patient within2) Topic of the Month: immunosuppressants in neurologyIn the first segment, Dr. Ted Burns talks with Dr. Richard Morton about his Neurology and the Humanities paper, "Discovering the Patient Within." In the second part of the podcast, Dr. Stacey Clardy focuses her interview with Dr. Anne Cross on immunosuppressants in neurology. Disclosures can be found at Neurology.org.DISCLOSURES:Dr. Burns serves as a section editor for the Neurology® podcast; serves on advisory boards for Argenx, UCB, and CSL Behring; receives travel or speaker honoraria from Argenx and Alexion; and received support for consulting from UCB Pharma and CSL Behring.Dr. Morton reports no disclosures. Dr. Clardy has received research support from Western Institute for Biomedical Research (WIBR).Dr. Cross has served on advisory boards for Roche and Genentech; has served on editorial boards for Brain Pathology, Journal of Neuroimmunology, and Annals of Clinical Translational Neurology; receives research support from Roche, Teva Neuroscience, OBOE, NIH, Barnes-Jewish Hospital Foundation, and Conrad N Hilton Foundation; consults with Biogen, Sanofi-Aventis/Genzyme, Novartis, Teva Neuroscience, Gerson Lehrman Group, Guidepoint Global, LLC, AbbVie, EMD Serono, Genentech, and Bayer; and receives honoraria from Projects in Knowledge, Prime Education, Inc., Race to Erase MS, Conrad N. Hilton Foundation, and WebMD.

July 18 2017 Issue Jul 17, 2017

Show notes

Show description/summary:1) Diagnosis of DWI-negative acute ischemic stroke: a meta-analysis 2) Topic of the Month: Multiple sclerosis therapeutics and pediatric multiple sclerosis patientsThis podcast begins and closes with Dr. Robert Gross, Editor-in-Chief, briefly discussing highlighted articles from the July 18, 2017 issue of Neurology. In the first segment, Dr. Kevin Barrett talks with Dr. Brian L. Edlow about his paper on the diagnosis of DWI-negative acute ischemic stroke: a meta-analysis. In the second part of the podcast Dr. Stacey Clardy focuses her interview with Dr. Emmanuelle Waubant on MS therapeutics and pediatric MS patients. Disclosures can be found at Neurology.org.DISCLOSURES:Dr. Barrett has served on the editorial boards of both Neurology® and The Neurohospitalist; receives publishing royalities from the book Stroke; and receives research support from NINDS.Dr. Edlow receives research support from Guger Technologies, NIH, American Academy of Neurology/American Brain Foundation, and the James S. McDonnell Foundation.Dr. Clardy received research support from Western Institute for Biomedical Research (WIBR).Dr. Waubant volunteers on a Novartis advisory board; serves on the editorial board of Annals of Clinical and Translational Neurology; serves as editor of MSARD; receives royalties from the publication of the book Demyelinating disorders of the central nervous system in childhood; and receives research support from Roche, Novartis, NIH, National MS Society, and Race to Erase MS.

July 11 2017 Issue Jul 10, 2017

Show notes

Show description/summary:1) Neurology® Neuroimmunology & Neuroinflammation: Antiepileptic drug therapy in patients with Autoimmune Epilepsy3) Topic of the Month: immunotherapy in neurologyThis podcast begins and closes with Dr. Robert Gross, Editor-in-Chief, briefly discussing highlighted articles from the July 11, 2017 issue of Neurology. In the first segment, Dr. Lara Marcuse talks with Dr. Anteneh Feyissa about his Neurology: Neuroimmunology & Neuroinflammation paper on antiepileptic drug therapy in patients with autoimmune epilepsy. In the second part of the podcast Dr. Stacey Clardy focuses her interview with Dr. Jeffrey A. Cohen on new immunotherapies in neurology. Disclosures can be found at Neurology.org.DISCLOSURES: Dr. Clardy received research support from Western Institute for Biomedical Research (WIBR). Dr. Cohen has served on scientific advisory boards for Adamas, Celgene, Genentech, Genzyme/Sanofi, Merck, and Novartis; serves as co-editor for Multiple Sclerosis Journal; receives publishing royalties from Multiple Sclerosis Therapeutics (Cambridge University Press, 4th ed., 2011); and has received research support form the Department of Defense, NIH, National MS Society, and Consortium of MS Centers. All other participants report no disclosures.

July 4 2017 Issue Jul 03, 2017

Show notes

Show description/summary:1) Intake of dairy foods and risk of Parkinson disease 2) Topic of the Month: Immunotherapies in neurology This podcast begins and closes with Dr. Robert Gross, Editor-in-Chief, briefly discussing highlighted articles from the July 4, 2017 issue of Neurology. In the first segment, Dr. Michelle Fullard talks with Dr. Katherine C. Hughes about her paper on intake of dairy foods and risk of Parkinson disease. In the second part of the podcast, Dr. Stacey Clardy focuses her interview with Dr. Dennis Bourdette on new immunotherapies in neurology. Disclosures can be found at Neurology.org.DISCLOSURES: Dr. Fullard has received training support from NIH. Dr. Hughes received research support from the U.S. Department of Defense. Dr. Clardy received research support from Western Institute for Biomedical Research (WIBR). Dr. Bourdette serves as an editorial board member on Neurology®, receives funding for travel from the National Multiple Sclerosis Society, the Consortium of MS Centers, and the Paralyzed Veterans of America; consults with Magellan Health and is a patient consultant for Best Doctors, Inc.; has a patent and a second patent pending for drug treatments of multiple sclerosis; and serves as a PI for the National MS Society.

Our TOPPODCAST Picks

Follow Us

Stay Connected

Related Podcasts

Links

Stay Connected